Cancer Research Meeting Calendar Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tweddle, D. A.
Right arrow Articles by Lunec, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tweddle, D. A.
Right arrow Articles by Lunec, J.
[Cancer Research 61, 8-13, January 1, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Evidence for the Development of p53 Mutations after Cytotoxic Therapy in a Neuroblastoma Cell Line1

Deborah A. Tweddle2, Archie J. Malcolm, Nick Bown, Andrew D. J. Pearson and John Lunec

Cancer Research Unit, The Medical School, University of Newcastle, NE2 4HH [D. A. T., J. L.]; Departments of Child Health [D. A. T., A. D. J. P.] and Pathology [A. J. M.], Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP; and Department of Biochemistry and Genetics, University of Newcastle, NE2 4AA [N. B.], United Kingdom

p53 mutations are rare in neuroblastomas at diagnosis perhaps accounting for their initial response to therapy, but advanced neuroblastoma frequently relapses, and it is possible that p53 mutations develop later. Two neuroblastoma cell lines derived from the same patient before [SKNBE(1n)] and after [SKNBE(2c)] cytotoxic therapy were analyzed for the presence of chromosome 17 and p53 genes by fluorescent in situ hybridization, p53 mutations by DNA sequencing, and p53 function after irradiation by studying the transcription of p53-regulated genes, cell cycle arrest, and induction of apoptosis. The SKNBE(1n) cell line was wild-type for p53, had two p53 genes, two copies of chromosome arm 17p and showed functional p53 after irradiation. The SKNBE(2c) cell line derived from the same patient 5 months later at relapse had loss of an entire chromosome 17, resulting in hemizygosity for the p53 locus on 17p and a missense p53 mutation in exon 5, and p53 was not functional after irradiation. The appearance of a p53 mutation in a cell line derived from a relapsed neuroblastoma suggests that this may be a mechanism of resistance to therapy. If p53 mutations develop frequently in relapsed neuroblastoma, cytotoxic agents more sensitive to mutant p53 might be more effective at relapse.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
R. A. Daniel, A. L. Rozanska, H. D. Thomas, E. A. Mulligan, Y. Drew, D. J. Castelbuono, Z. Hostomsky, E. R. Plummer, A. V. Boddy, D. A. Tweddle, et al.
Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
Clin. Cancer Res., February 15, 2009; 15(4): 1241 - 1249.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Michaelis, F. Rothweiler, D. Klassert, A. von Deimling, K. Weber, B. Fehse, B. Kammerer, H. W. Doerr, and J. Cinatl Jr.
Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3
Cancer Res., January 15, 2009; 69(2): 416 - 421.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Xue, M. Haber, C. Flemming, G. M. Marshall, R. B. Lock, K. L. MacKenzie, K. V. Gurova, M. D. Norris, and A. V. Gudkov
p53 Determines Multidrug Sensitivity of Childhood Neuroblastoma
Cancer Res., November 1, 2007; 67(21): 10351 - 10360.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
D. Goldschneider, E. Horvilleur, L.-F. Plassa, M. Guillaud-Bataille, K. Million, E. Wittmer-Dupret, G. Danglot, H. d. The, J. Benard, E. May, et al.
Expression of C-terminal deleted p53 isoforms in neuroblastoma
Nucleic Acids Res., November 14, 2006; 34(19): 5603 - 5612.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Van Maerken, F. Speleman, J. Vermeulen, I. Lambertz, S. De Clercq, E. De Smet, N. Yigit, V. Coppens, J. Philippe, A. De Paepe, et al.
Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
Cancer Res., October 1, 2006; 66(19): 9646 - 9655.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Asgharzadeh, R. Pique-Regi, R. Sposto, H. Wang, Y. Yang, H. Shimada, K. Matthay, J. Buckley, A. Ortega, and R. C. Seeger
Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification.
J Natl Cancer Inst, September 6, 2006; 98(17): 1193 - 1203.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
J. R. Elison, D. Cobrinik, N. Claros, D. H. Abramson, and T. C. Lee
Small Molecule Inhibition of HDM2 Leads to p53-Mediated Cell Death in Retinoblastoma Cells.
Arch Ophthalmol, September 1, 2006; 124(9): 1269 - 1275.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. Brignole, D. Marimpietri, F. Pastorino, B. Nico, D. Di Paolo, M. Cioni, F. Piccardi, M. Cilli, A. Pezzolo, M. V. Corrias, et al.
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
J Natl Cancer Inst, August 16, 2006; 98(16): 1142 - 1157.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Carr, E. Bell, A. D.J. Pearson, U. R. Kees, H. Beris, J. Lunec, and D. A. Tweddle
Increased Frequency of Aberrations in the p53/MDM2/p14ARF Pathway in Neuroblastoma Cell Lines Established at Relapse
Cancer Res., February 15, 2006; 66(4): 2138 - 2145.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-F. Lavoie, L. LeSauteur, J. Kohn, J. Wong, O. Furtoss, C. J. Thiele, F. D. Miller, and D. R. Kaplan
TrkA Induces Apoptosis of Neuroblastoma Cells and Does So via a p53-dependent Mechanism
J. Biol. Chem., August 12, 2005; 280(32): 29199 - 29207.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Karlsson, A. Edsjo, S. Pahlman, and H. M. Pettersson
Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia
Mol. Cancer Ther., July 1, 2005; 4(7): 1128 - 1135.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ogawa, H. Hori, T. Ohta, K. Onozato, M. Miyahara, and Y. Komada
Sensitivity to Gemcitabine and Its Metabolizing Enzymes in Neuroblastoma
Clin. Cancer Res., May 1, 2005; 11(9): 3485 - 3493.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Karlsson, I. Ora, I. Porn-Ares, and S. Pahlman
Arsenic Trioxide-Induced Death of Neuroblastoma Cells Involves Activation of Bax and Does Not Require p53
Clin. Cancer Res., May 1, 2004; 10(9): 3179 - 3188.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
E. Blanc, D. Goldschneider, E. Ferrandis, M. Barrois, G. Le Roux, S. Leonce, S. Douc-Rasy, J. Benard, and G. Raguenez
MYCN Enhances P-gp/MDR1 Gene Expression in the Human Metastatic Neuroblastoma IGR-N-91 Model
Am. J. Pathol., July 1, 2003; 163(1): 321 - 331.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Yang, M. S. Merchant, M. E. Romero, M. Tsokos, L. H. Wexler, U. Kontny, C. L. Mackall, and C. J. Thiele
Induction of Caspase 8 by Interferon {gamma} Renders Some Neuroblastoma (NB) Cells Sensitive to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) but Reveals That a Lack of Membrane TR1/TR2 Also Contributes to TRAIL Resistance in NB
Cancer Res., March 1, 2003; 63(5): 1122 - 1129.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Cui, A. Schroering, and H.-F. Ding
p53 Mediates DNA Damaging Drug-induced Apoptosis through a Caspase-9-dependent Pathway in SH-SY5Y Neuroblastoma Cells
Mol. Cancer Ther., July 1, 2002; 1(9): 679 - 686.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Keshelava, J. J. Zuo, P. Chen, S. N. Waidyaratne, M. C. Luna, C. J. Gomer, T. J. Triche, and C. P. Reynolds
Loss of p53 Function Confers High-Level Multidrug Resistance in Neuroblastoma Cell Lines
Cancer Res., August 1, 2001; 61(16): 6185 - 6193.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.